741 related articles for article (PubMed ID: 31559638)
1. Novel Medications for the Treatment of Migraine.
Ceriani CEJ; Wilhour DA; Silberstein SD
Headache; 2019 Oct; 59(9):1597-1608. PubMed ID: 31559638
[TBL] [Abstract][Full Text] [Related]
2. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
Tepper SJ
Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
[TBL] [Abstract][Full Text] [Related]
3. Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review.
Yuan H; Spare NM; Silberstein SD
Headache; 2019 Jul; 59 Suppl 2():20-32. PubMed ID: 31291020
[TBL] [Abstract][Full Text] [Related]
4. Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018.
Tepper SJ
Headache; 2018 Nov; 58 Suppl 3():276-290. PubMed ID: 30403405
[TBL] [Abstract][Full Text] [Related]
5. Future prophylactic treatments in migraine: Beyond anti-CGRP monoclonal antibodies and gepants.
Do TP; Al-Saoudi A; Ashina M
Rev Neurol (Paris); 2021 Sep; 177(7):827-833. PubMed ID: 34294458
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex.
Porreca F; Navratilova E; Hirman J; van den Brink AM; Lipton RB; Dodick DW
Cephalalgia; 2024 Mar; 44(3):3331024241238153. PubMed ID: 38477313
[TBL] [Abstract][Full Text] [Related]
7. CGRP and Migraine: The Role of Blocking Calcitonin Gene-Related Peptide Ligand and Receptor in the Management of Migraine.
Maasumi K; Michael RL; Rapoport AM
Drugs; 2018 Jun; 78(9):913-928. PubMed ID: 29869205
[TBL] [Abstract][Full Text] [Related]
8. Basic Considerations for the Use of Monoclonal Antibodies in Migraine.
Levin M; Silberstein SD; Gilbert R; Lucas S; Munsie L; Garrelts A; Kennedy K; Everman N; Pearlman E
Headache; 2018 Nov; 58(10):1689-1696. PubMed ID: 30426478
[TBL] [Abstract][Full Text] [Related]
9. Targeting CGRP and 5-HT
Moreno-Ajona D; Chan C; Villar-Martínez MD; Goadsby PJ
Headache; 2019 Jul; 59 Suppl 2():3-19. PubMed ID: 31291016
[TBL] [Abstract][Full Text] [Related]
10. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
Chiang CC; Schwedt TJ
Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
[TBL] [Abstract][Full Text] [Related]
11. CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention.
Caronna E; Alpuente A; Torres-Ferrus M; Pozo-Rosich P
Handb Clin Neurol; 2024; 199():107-124. PubMed ID: 38307640
[TBL] [Abstract][Full Text] [Related]
12. Gepants for the treatment of migraine.
Negro A; Martelletti P
Expert Opin Investig Drugs; 2019 Jun; 28(6):555-567. PubMed ID: 31081399
[TBL] [Abstract][Full Text] [Related]
13. Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale.
Cohen F; Yuan H; Silberstein SD
BioDrugs; 2022 May; 36(3):341-358. PubMed ID: 35476215
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans.
de Vries T; Villalón CM; MaassenVanDenBrink A
Pharmacol Ther; 2020 Jul; 211():107528. PubMed ID: 32173558
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of new acute treatments for migraine.
Lupi C; Benemei S; Guerzoni S; Pellesi L; Negro A
Expert Opin Drug Metab Toxicol; 2019 Mar; 15(3):189-198. PubMed ID: 30714429
[TBL] [Abstract][Full Text] [Related]
16. CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?
Favoni V; Giani L; Al-Hassany L; Asioli GM; Butera C; de Boer I; Guglielmetti M; Koniari C; Mavridis T; Vaikjärv M; Verhagen I; Verzina A; Zick B; Martelletti P; Sacco S;
J Headache Pain; 2019 Mar; 20(1):27. PubMed ID: 30866804
[TBL] [Abstract][Full Text] [Related]
17. CGRP as the target of new migraine therapies - successful translation from bench to clinic.
Edvinsson L; Haanes KA; Warfvinge K; Krause DN
Nat Rev Neurol; 2018 Jun; 14(6):338-350. PubMed ID: 29691490
[TBL] [Abstract][Full Text] [Related]
18. The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse.
van Hoogstraten WS; MaassenVanDenBrink A
J Headache Pain; 2019 May; 20(1):54. PubMed ID: 31096904
[TBL] [Abstract][Full Text] [Related]
19. Targeting to 5-HT1F receptor subtype for migraine treatment: lessons from the past, implications for the future.
Mitsikostas DD; Tfelt-Hansen P
Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):241-9. PubMed ID: 22934751
[TBL] [Abstract][Full Text] [Related]
20. Medications Approved for Preventing Migraine Headaches.
Spindler BL; Ryan M
Am J Med; 2020 Jun; 133(6):664-667. PubMed ID: 32145209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
